Clinical Trial Search

Primary: To Determine if Adjunct Aripiprazole Will Resolve or Improve Prolactin Related Hormonal Side Effects (Amenorrhea, Oligomenorrhea, Galactorrhea). — 11; 7 Participants

Primary: Height (cm) Z-score at Study Visit — 0.40; 0.09 z-score — p=<0.001

Primary: Percentage of Subjects That Achieved PRL Normalization as Defined by a Serum Prolactin Level Less Than 25ng/mL at Any Time Point During the Study Treatment Period. — 6…

Primary: Assessment of Negative Symptoms and Neuroleptic Induced Deficit Syndromes by Objective Rating Scales — -1.30; -0.28; -0.66; -0.70 units on a scale

Primary: Trabecular Bone Mineral Density in the Ultradistal Radius — 192.9; 197.2; 191.0; 194.6 mg/cm^3

Primary: Change From Baseline in Mean Unified Huntington's Disease (HD) Rating Scale Total Maximal Chorea (UHDRS TMC) Score — -2.4 score on a scale — p=0.27

Primary: Change in Positive And Negative Syndrome Scale (PANSS) Total Score From Baseline to Endpoint — -38.37; -37.24 scores on a scale — p=0.784

Primary: Evaluate the Number of Clinical Events (Pooled) Occurring Between 3-15 Months Following a Switch/Stabilization of the Antipsychotic Agents Among Patients Who Receive…

Primary: Peak Plasma Concentration (Cmax) for Active Moiety — 39.6; 54.1; 53.2; 61.0 ng/mL

Primary: Positive Symptom Item Scores by Week and Treatment Group — 15.5; 15.5; 14.6; 15.1 units on a scale

Primary: Change Over Time in Frequency of Heavy Drinking Days (Used to Evaluate Treatment Efficacy) — -.11; .68 heavy drinking days per week — p=0.054

Primary: Number of Participants With Treatment-related Adverse Events as Assessed

Primary: Change in Eating Disorder Inventory-2 Drive for Thinness Subscale (DT) — 1.36; 3.93 units on a scale

Primary: Presence of a Cortical (C) Type of Cataractogenic Potential Events in Participants as Assessed and Agreed by 2 Independent, Treatment-masked Ophthalmologists Using the…

Primary: Adverse Events — 10; 13 Participants

Primary: Percentage of Participants That Responded to Treatment — 62.8; 56.8 percentage of response — p=.61

Primary: Medication Satisfaction Questionnaire (MSQ) Score Change From Baseline to the Week 6 Endpoint. — 2.5; 2.3; 2.4 Points on a scale — p=<0.001

Primary: Change From Baseline in Total Positive and Negative Syndrome Scale (PANSS) Score at Week 96 — 73.00; 18.24 Units on a scale

Primary: Overall Response Rate (ORR) at 2 Months — 0 Participants

Primary: Area Under the Curve (AUC) for Active Moiety, 9-hydroxy-risperidone and Risperidone

Primary: Change From Baseline in Body Weight — 2.32; 4.23; 2.87 kilograms

Primary: Steady-state Average Plasma Concentration (Cavg,ss) of Risperidone and Total Active Moiety — 5.150; 10.200; 43.730; 44.049 ng/mL

Primary: Time to Recurrence of a Mood Episode (Risperidone LAI Versus Placebo) — 293.39; 270.47 days — p=0.057

Primary: Galactorrhea — 0; 56 percentage of participants

Primary: Summary of Participants With Treatment-Emergent Adverse Events (TEAE) — 4; 4; 7; 11 Participants

Primary: Total Positive and Negative Syndrome Scale (PANSS) Score Between Baseline and 24 Weeks. — 89.0; 89.7; 80.0; 80.8 score on a scale

Primary: Change From Baseline in Positive and Negative Syndrome Scale (PANSS) Total Score at Week 26 — 68.9; 28.1 Units on a scale

Primary: Positive and Negative Syndromes Scale (PANSS) Total Score at Week 2 — 55.53 Units on a scale

Primary: PANSS Total Score Mean Change From Baseline to Endpoint — -24.6; -24.7; -11.0 units on a scale

Primary: Change in the Positive and Negative Syndrome Scale (PANSS) Total Score for Schizophrenia — -18.6; -17.9 Scores on a scale